AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...
The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic ...
LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VYGR), a biotechnology company dedicated to advancing ...
Launched by AKF in November 2020, the UCKD Project works to expand access to genetic testing, reduce systemic inequities, engage providers and empower patients. Implementation groups have concentrated ...
Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics ...
Inc. and Vertex Pharmaceuticals Inc.; Champion Sponsors Alexion, AstraZeneca Rare Disease; Boehringer Ingelheim; Natera; Novo Nordisk and Sanofi. The American Kidney Fund (AKF) fights kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback